QT prolongation due to targeted anticancer therapy
Journal Title: OncoReview - Year 2016, Vol 6, Issue 3
Abstract
A growing number of targeted anticancer agents has shown the unexpected ability to induce QT interval prolongation. In addition, standard chemotherapeutics and a variety of conditions such as electrolyte abnormalities, endocrine disorders, cardiac diseases, nutritional disturbances and other factors may be associated with long QT syndrome in cancer patients. Prolongation of the QT interval can lead to life-threatening ventricular arrhythmias, including ‘torsade de pointes’ (TdP). The association between long QT interval and ventricular arrhythmias remains the subject of many controversies.The QT interval represents the time interval of both ventricular depolarization and repolarization. Not only abnormalities of ion channels, but also changes in the myocardial microarchitecture and other factors and disorders frequently seen in cancer patients may participate in its prolongation and potential risk of ventricular arrhythmias.The aim of this review was to summarize current knowledge about QT prolongation in cancer patients with the special focus on targeted therapy.
Authors and Affiliations
Lucia Setteyova, Ljuba Bacharova, Beata Mladosievicova
Keywords
Related Articles
- EP ID EP80363
- DOI -
- Views 226
- Downloads 0
ICOS Annual Conference Meeting in Washington DC - importance for scientific activity in Eastern Europe
Badanie kliniczne III fazy oceniające zastosowanie pazopanibu w leczeniu raka nerki – komentarz do badania
The mTOR signalling pathways in the pathogenesis and treatment of neuroendocrine tumours
Neuroendocrine tumours (NET) are a rare and heterogeneous group of neoplasms.The majority of patients are diagnosed with locally advanced or metastatic disease, and curative surgery is rarely an option. Treatment approac...
Octreotide LAR in neuroendocrine tumors - a summary of the experience
Neuroendocrine tumors are a rare and heterogeneous group of neoplasms. Most of the patient is diagnosed with locally advanced or metastatic disease and curative surgery is rarely an option. Somatostatin analogues have b...
Mięsakorak trzonu macicy jako trzeci nowotwór pacjentki - opis przypadku i omówienie aktualnych zaleceń postępowania
Postęp w leczeniu systemowym przerzutowego raka nerki związany jest z rejestracją nowych leków. Przyniosło to poprawę wyników leczenia, ale zmusza również do dokonywania wyboru leku. Decyzja ta jest szczególnie istotna w...